Drug Combination Details
| General Information of the Combination (ID: C67401) | |||||
|---|---|---|---|---|---|
| Name | Isoliquiritigenin NP Info | + | TNF-related apoptosis inducing ligand Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colon cancer
[ICD-11: 2B90]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP10 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HT29 | CVCL_A8EZ | Colorectal adenocarcinoma | Mus musculus | ||
| Experimental
Result(s) |
Isoliquiritigenin has the potential to overcome resistance to TRAIL in cancer cells and its chemopreventive effects may depend on TRAIL function. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Isoliquiritigenin has the potential to overcome resistance to TRAIL in cancer cells and its chemopreventive effects may depend on TRAIL function. | |||||
